Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis

Publisher： Karger

E-ISSN： 1421-9662|137|3|163-172

ISSN： 0001-5792

Source： Acta Haematologica, Vol.137, Iss.3, 2017-04, pp. : 163-172

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

By  

Acta Haematologica, Vol. 132, Iss. 2, 2014-03 ,pp. : 211-219

Karger

Access to resources Recommend Favorite

Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience

By  

Oncology, Vol. 89, Iss. 4, 2015-07 ,pp. : 196-204

Karger

Access to resources Recommend Favorite

Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 605-606

John Wiley & Sons Inc

Access to resources Recommend Favorite

The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 2, 2015-02 ,pp. : 109-114

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cyclophosphamide‐based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma

By  

JOURNAL OF CLINICAL APHERESIS, Vol. 30, Iss. 3, 2015-06 ,pp. : 176-182

John Wiley & Sons Inc

Access to resources Recommend Favorite